Spartalizumab (anti-PD-1)

目录号：A2017         批次号: A201703

打印

Spartalizumab (anti-PD-1)是一种针对PD-1的人源IgG4抗体，抑制PD-L1和PD-L2与PD-1的结合。PDR001可与PD-1以高亲和力结合，抑制其生物活性；MW: 145.8 KD。

抗体信息

CAS号 1935694-88-4
配制 PBS buffer, pH 7.2
推荐同型对照 Human IgG4
来源 CHO cells
储存条件
(自收到货起)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
除菌 0.2 μM filtered
纯度 99%
蛋白浓度 4.54 mg/ml
内毒素 <1 EU/mg

Spartalizumab (anti-PD-1)在文献中得到引用

Vinburnine potentiates anti-PD1 immunotherapy in melanoma through IL-24 secretion via P38/MAPK/ATF3 signaling [ J Exp Clin Cancer Res, 2025, 44(1):255] PubMed: 40866941
Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α. [ Elife, 2020, 9] PubMed: 32091388

禁止用于人体及治疗！